

DAFTAR PUSTAKA

1. Dhingra P, Dhingra S. Cholesteatoma and Chronic Otitis Media. In: *Disease of Ear, Nose, and Throat & Head and Neck Surgery*. New Delhi: Elsevier, 2018: 71–82.
2. Browning GG, Weir J, Kelly G, et al. Chronic Otitis Media. In: Watkinson JC, Clarke RW (eds) *Scott-Brown's Otorhinolaryngology Head and Neck Surgery*. New York: Taylor & Francis Group, 2019: 977–1020.
3. Menkes RI. Pedoman Nasional Pelayanan Kedokteran: Tatalaksana Otitis Media Supuratif Kronik. *Keputusan Menteri Kesehatan Republik Indonesia* 2018; 1–130.
4. Cantone E, di Nola C, de Corso E, et al. Endotyping of Cholesteatoma: Which Molecular Biomarkers? A Systematic Review. *J Pers Med* 2022; 12: 1347–57.
5. Jovanovic I, Zivkovic M, Djuric T, et al. Perimatrix of middle ear cholesteatoma: A granulation tissue with a specific transcriptomic signature. *Laryngoscope* 2020; 130: E220-7.
6. Xie S, Jin L, Yin T, et al. Microarray analysis and functional prediction of differentially expressed circular RNAs in acquired middle ear cholesteatoma. *Biomed Eng Online* 2021; 20: 1–13.
7. Hamed MA, Nakata S, Sayed RH, et al. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future perspectives. *Clin Exp Otorhinolaryngol* 2016; 9: 298–308.
8. Kuo CL, Shiao AS, Yung M, et al. Updates and knowledge gaps in cholesteatoma research. *Biomed Res Int* 2015; 2015: 1–17.
9. Uzun T, Çaklı H, Coşan DT, et al. In vitro study on immune response modifiers as novel medical treatment options for cholesteatoma. *Int J Pediatr Otorhinolaryngol* 2021; 145: 1–8.
10. Si Y, Chen Y bin, Chen SJ, et al. TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction. *Sci Rep* 2015; 5: 1–13.
11. Iwamoto Y, Nishikawa K, Imai R, et al. Intercellular Communication between Keratinocytes and Fibroblasts Induces Local Osteoclast Differentiation: a Mechanism Underlying Cholesteatoma-Induced Bone Destruction. *Mol Cell Biol* 2016; 36: 1610–20.
12. Drakskog C, de Klerk N, Westerberg J, et al. Extensive qPCR analysis reveals altered gene expression in middle ear mucosa from cholesteatoma patients. *PLoS One* 2020; 15: 1–19.
13. Maniu A, Harabagiu O, Schrepler MP, et al. Molecular biology of cholesteatoma. *Romanian Journal of Morphology and Embryology* 2014; 55: 7–13.
14. Pusalkar AG. Cholesteatoma and Its Management. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2015; 67: 201–4.
15. Jackler RK, Santa Maria PL, Varsak YK, et al. A new theory on the pathogenesis of acquired cholesteatoma: Mucosal traction. *Laryngoscope* 2015; 125: S1–S14.

16. Meyer TA, Jr CJS, Lambert PL. Cholesteatoma. In: Johnson JT, Rosen CA (eds) *Bailey's Head & Neck Surgery Otolaryngology Vol 2*. Philadelphia: Lippincott Williams & Wilkins, 2014: 2433–43.
17. Novianti D. *Tesis Perbedaan Frekuensi Pembentukan Biofilm Bakteri Aerob pada Otitis Media Supuratif Kronis Tipe Aman Fase Aktif dengan Tipe Bahaya di RSUP Dr. M. Djamil Padang*. Universitas Andalas, 2016.
18. Schürmann M, Greiner JFW, Volland-Thurn V, et al. Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS. *Cells* 2020; 9: 1–17.
19. Mahfuzah, Djamin R, Sulaiman AB, et al. Analysis of Toll-Like Receptors-2 Expression in Patients with Chronic Suppurative Otitis Media with and Without Cholesteatoma. *journal of Xi'an Shiyu University* 2022; 65: 25–35.
20. Jotic A, Jesic S, Zivkovic M, et al. Polymorphisms in Toll-like receptors 2 and 4 genes and their expression in chronic suppurative otitis media. *Auris Nasus Larynx* 2015; 42: 431–7.
21. Jung SY, Kim D, Park DC, et al. Toll-like receptors: Expression and roles in otitis media. *Int J Mol Sci* 2021; 22: 1–17.
22. Lee HY, Park MS, Byun JY, et al. Expression of pattern recognition receptors in cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2014; 271: 245–53.
23. Szczepański M, Szyfter W, Jenek R, et al. Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2006; 263: 603–7.
24. Granath A, Cardell LO, Uddman R, et al. Altered Toll- and Nod-like receptor expression in human middle ear mucosa from patients with chronic middle ear disease. *Journal of Infection* 2011; 63: 174–6.
25. Westerberg J. *Dissertations Middle ear cholesteatoma. Surgical outcome and aspects of the innate immunity*. Linköping University, 2020.
26. Leichtle A, Kurabi A, Leffers D, et al. Immunomodulation as a Protective Strategy in Chronic Otitis Media. *Front Cell Infect Microbiol* 2022; 12: 1–16.
27. Hirai H, Kariya S, Okano M, et al. Expression of toll-like receptors in chronic otitis media and cholesteatoma. *Int J Pediatr Otorhinolaryngol* 2013; 77: 674–6.
28. Ahmed Z, Khan TZ, Rahim DU. Otogenic complications of otitis media : experience at tertiary care hospital Received : Accepted : *Pak Surg* 2016; 32: 49–53.
29. Rutkowska J, Özgirgin N, Olszewska E. Cholesteatoma definition and classification: A literature review. *Journal of International Advanced Otolaryngology* 2017; 13: 266–71.
30. Walker D, Shinnars MJ. Congenital cholesteatoma. *Pediatr Ann* 2016; 45: e167-70.
31. Kuo C-L. Recent Advances in Understanding the Pathogenesis of Acquired Cholesteatoma. In: Lalwani AK, Pfister MH (eds) *Recent Advances in Otolaryngology—Head and Neck Surgery*. New Delhi: Jaypee Brothers Medical Publishers, 2016: 167–90.

32. Hidayat R. Pathophysiological to Clinical Aspects of Chronic Suppurative Otitis Media (CSOM): Narrative Literature Review. *Archives of The Medicine and Case Reports* 2022; 3: 246–55.
33. Castle JT. Cholesteatoma Pearls: Practical Points and Update. *Head Neck Pathol* 2018; 12: 419–29.
34. Kanemaru SI, Kikkawa Y, Omori K, et al. Bone destructive mechanisms of cholesteatoma. *Laryngoscope* 2010; 120: 68.
35. Xie S, Wang X, Ren J, et al. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma. *European Archives of Oto-Rhino-Laryngology* 2017; 274: 2071–8.
36. Nguyen KH, Suzuki H, Ohbuchi T, et al. Possible participation of acidic pH in bone resorption in middle ear cholesteatoma. *Laryngoscope* 2014; 124: 245–50.
37. Xie S, Xiang Y, Wang X, et al. Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways. *Laryngoscope* 2016; 126: 1923–30.
38. Baratawidjaja K, Rengganis I. Gambaran Umum Sistem Imun. In: Baratawidjaja K, Rengganis I (eds) *Imunologi Dasar*. Jakarta: Badan Penerbit FKUI, 2018: 23–52.
39. Mehraj U, Nisar S, Qayoom H, et al. The Innate and Adaptive Immunity. In: Mir MA (ed) *Basic and Fundamentals of Immunology*. New York: Nova Science Publishers, Inc, 2020: 117–38.
40. El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an overview. *Bull Natl Res Cent* 2019; 43: 1–12.
41. Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. *Biomed Res Int* 2021; 2021: 1–14.
42. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. *Front Immunol* 2014; 5: 1–8.
43. Behzadi P, García-Perdomo HA, Karpiński TM. Toll-Like Receptors: General Molecular and Structural Biology. *Journal of Immunology Research* 2021; 2021: 1–21.
44. Bryant CE, Gay NJ, Heymans S, et al. Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. *Critical Reviews in Biochemistry and Molecular Biology* 2015; 50: 359–79.
45. Dunne DW, Shaw A, Bockenstedt LK, et al. Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults. *PLoS One* 2010; 5: 1–7.
46. Wang Z, Ni X, Zhang L, et al. Toll-like receptor 4 and inflammatory micro-environment of pancreatic islets in type-2 diabetes mellitus: A therapeutic perspective. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2020; 13: 4261–72.
47. Smith RL, Hébert HL, Massey J, et al. Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. *Arch Dermatol Res* 2016; 308: 201–5.
48. Edward Y, Decroli E, Ali H, et al. Expression of CCL27 in Middle Ear Cholesteatoma. *Open Access Maced J Med Sci* 2021; 9: 240–3.

49. Jiang H, Si Y, Li Z, et al. TREM-2 promotes acquired cholesteatoma-induced bone destruction by modulating TLR4 signaling pathway and osteoclasts activation. *Sci Rep* 2016; 6: 1–15.
50. Imai R, Sato T, Iwamoto Y, et al. Osteoclasts Modulate Bone Erosion in Cholesteatoma via RANKL Signaling. *JARO - Journal of the Association for Research in Otolaryngology* 2019; 20: 449–59.
51. Schürmann M, Oppel F, Shao S, et al. Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism. *Cell Communication and Signaling* 2021; 19: 1–15.
52. Mazgaen L, Gurung P. Recent advances in lipopolysaccharide recognition systems. *Int J Mol Sci* 2020; 21: 1–18.
53. Dahlan SM. Menggunakan Rumus Besar Sampel Secara Benar. In: *Besar Sampel dan Cara Pengambilan Sampel*. Jakarta: Salemba Medika, 2013: 35–72.
54. Sastroasmoro S, Ismael S. Perkiraan Besar Sampel. In: *Dasar-dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, 2008: 302–32.
55. Mahajan T, Dass A, Gupta N, et al. Bacteriological Profile in Attico-antral type of Chronic Suppurative Otitis Media. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2019; 71: 1412–21.
56. Rosito LPS, da Silva MNL, Selaimen FA, et al. Characteristics of 419 patients with acquired middle ear cholesteatoma. *Braz J Otorhinolaryngol* 2017; 83: 126–31.
57. Keita A, Diallo I, Diallo MA, et al. Cholesteatoma of the middle ear: about 50 cases in Donka University Hospital. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2022; 8: 787–91.
58. Im GJ, do Han K, Park KH, et al. Rate of chronic otitis media operations and cholesteatoma surgeries in South Korea: a nationwide population-based study (2006–2018). *Sci Rep* 2020; 10: 1–10.
59. Handoko E, Indrasworo D, Harun Nur Salim A. Hubungan derajat kolesteatoma dengan keberhasilan operasi mastoidektomi radikal pada penderita otitis media supuratif kronis. *Oto Rhino Laryngologica Indonesiana* 2019; 49: 99–107.
60. Li J, Jufas N, Forer M, et al. Incidence and trends of middle ear cholesteatoma surgery and mastoidectomy in Australia—A national hospital morbidity database analysis. *Laryngoscope Investig Otolaryngol* 2022; 7: 210–8.
61. Natarajan K, Kurkure R, . S, et al. Management of advanced cholesteatoma: Madras ENT Research Foundation experience. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2020; 6: 1149–54.
62. Shwetha. Chronic otitis media with cholesteatoma: clinical presentation and surgical management. *International Journal of Otorhinolaryngology and Head and Neck Surgery* 2018; 4: 1212–19.
63. Mokbel Khalefa KM. Ten years incidence of intracranial complications of chronic suppurative otitis media. *Journal of Medical Research and Health Sciences* 2020; 3: 996–1001.
64. Lestari DY. *Tesis Perbedaan Kadar Lipopolisakarida Antara Otitis Media Supuratif Kronis Tipe Bahaya dengan Tipe Aman Fase Aktif*. Universitas Andalas, 2018.

65. Hifni A, Rian Hasni, Fiona Widyasari, et al. Comparison of Germ Patterns and Antimicrobial Susceptibility in Chronic Suppurative Otitis Media with Cholesteatoma and without Cholesteatoma in Dr. Mohammad Hoesin Hospital. *Bioscientia Medicina : Journal of Biomedicine and Translational Research* 2021; 5: 647–56.
66. Morin CD, Déziel E, Gauthier J, et al. An Organ System-Based Synopsis of *Pseudomonas aeruginosa* Virulence. *Virulence* 2021; 12: 1469–507.
67. Mittal R, Lisi C V., Gerring R, et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media. *J Med Microbiol* 2015; 64: 1103–16.
68. Si Y, Zhang ZG, Chen SJ, et al. Attenuated TLRs in middle ear mucosa contributes to susceptibility of chronic suppurative otitis media. *Hum Immunol* 2014; 75: 771–6.
69. Zaffaroni L, Peri F. Recent advances on Toll-like receptor 4 modulation: New therapeutic perspectives. *Future Med Chem* 2018; 10: 461–76.
70. Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. *Cellular and Molecular Life Sciences* 2021; 78: 1233–61.
71. Frickmann H. Cholesteatoma? A Potential Consequence of Chronic Middle Ear Inflammation. *Otolaryngology* 2012; 02: 1–8.
72. AlQranei MS, Senbanjo LT, Aljohani H, et al. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling. *BMC Immunol* 2021; 22: 1–16.

